Evidence map›Paper›PMID 38247567›Full record

ArticleAntibodies (Basel, Switzerland)2024

Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig

Hikaru Koga, Haruka Kuroi, Rena Hirano, Hiroyuki Hirayama, Yoshiaki Nabuchi, Taichi Kuramochi

Open access · goldAbstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Generation of Bispecific Antibodies Using FAST-Ig™.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hikaru KogaChugai Pharmaceutical Co., Ltd., Yokohama 244-8602, Japan.ORCID 0000-0001-9693-5334
Haruka KuroiChugai Pharmaceutical Co., Ltd., Yokohama 244-8602, Japan.
Rena HiranoChugai Pharmaceutical Co., Ltd., Yokohama 244-8602, Japan.
Hiroyuki HirayamaChugai Pharmaceutical Co., Ltd., Yokohama 244-8602, Japan.
Yoshiaki NabuchiChugai Pharmaceutical Co., Ltd., Yokohama 244-8602, Japan.
Taichi KuramochiChugai Pharmaceutical Co., Ltd., Yokohama 244-8602, Japan.ORCID 0000-0001-7242-7124

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bispecific antibodies (BsAbs) can bind to two different antigens, enabling therapeutic concepts that cannot be achieved with monoclonal antibodies. Immuno-competent mice are essential for validating drug discovery concepts, necessitating the development of surrogate mouse BsAbs. In this study, we explored the potential of FAST-Ig

Indexed as

bispecific antibodyFAST-Igorthogonal Fabsingle-cell productionsurrogate mouse bispecific antibody

Identifiers

PMID38247567
PMCPMC10801562
OpenAlexW4390507070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.